2,355 results match your criteria Endometrial Carcinoma* Obstetrics and Gynecology


Molecular Profiles of Mixed Endometrial Carcinoma.

Am J Surg Pathol 2020 Jun 26. Epub 2020 Jun 26.

Departments of Pathology and Laboratory Medicine.

Mixed endometrial carcinomas are defined as a combination of 2 or more distinct histologic subtypes, one of which must be a type II tumor comprising at least 5% of the tumor volume. The oncogenesis of these tumors remains unclear, particularly in light of the increasingly appreciated morphologic overlap among subtypes, as well as evolving molecular data. We evaluated 8 cases of mixed endometrial carcinoma, including 4 endometrioid (EC)/serous (SC), 1 SC/clear cell (CC), and 3 EC/CC cases, to study the underlying molecular features and oncogenic mechanisms at play. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001519DOI Listing

Atypical polypoid adenomyoma follow-up and management: Systematic review of case reports and series and meta-analysis.

Medicine (Baltimore) 2020 Jun;99(26):e20491

Clinic of Obstetrics and Gynecology, DINOGMI, IRCCS San Martino Hospital, University of Genova, Genova (GE), Italy.

Background: Atypical polypoid adenomyoma (APA) is a rare uterine tumor typically found in fertile age and associated with infertility. Among young nullipara women, conservative treatment is proposed despite the high recurrence rate and the association with endometrial cancer.Our aim was to assess the risk of recurrence with different conservative treatments in fertile ages and the prevalence of malignant or pre-malignant associated lesions to better address an adequate patient counselling when treatment modalities are discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020491DOI Listing

Identification of long noncoding RNA RP11-89K21.1 and RP11-357H14.17 as prognostic signature of endometrial carcinoma via integrated bioinformatics analysis.

Cancer Cell Int 2020 24;20:268. Epub 2020 Jun 24.

Department of Obstetrics and Gynaecology, Shengjing Hospital of China Medical University, No.36 Sanhao Street, Heping District, Shenyang, 110004 Liaoning China.

Background: Endometrial carcinoma (EC) is one of the most common malignant tumors in gynecology. The potential functions and mechanisms of long noncoding RNAs (lncRNAs) in the occurrence and progression of EC remains unclear. It's meaningful to explore lncRNAs signature for providing prognostic value of EC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-020-01359-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313119PMC

The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients.

Diagnostics (Basel) 2020 Jun 18;10(6). Epub 2020 Jun 18.

General Pathology Department, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.

Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10060414DOI Listing

Possibility of Targeting Claudin-2 in Therapy for Human Endometrioid Endometrial Carcinoma.

Reprod Sci 2020 Jun 16. Epub 2020 Jun 16.

Department of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo, 060-8556, Japan.

Claudin-2 (CLDN-2) is a leaky-type tight junction protein, and its overexpression increases tumorigenesis of some types of cancer cells. In the present study, to examine the possibility of targeting CLDN-2 in the therapy for endometrioid endometrial adenocarcinoma, we investigated the regulation and role of CLDN-2 in endometriosis and endometrioid endometrial adenocarcinoma. In endometrioid endometrial adenocarcinoma tissues, marked upregulation of CLDN-2 was observed together with malignancy, while in endometriosis tissues, a change in the localization of CLDN-2 was observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s43032-020-00230-6DOI Listing

MiR-486-5p Act as a Biomarker in Endometrial Carcinoma: Promotes Cell Proliferation, Migration, Invasion by Targeting MARK1.

Onco Targets Ther 2020 28;13:4843-4853. Epub 2020 May 28.

Department of Obstetrics and Gynecology, Ningbo First Hospital, Ningbo, Zhejiang 315035, People's Republic of China.

Background: miRNA expression acts as a potential biomarker in many diseases including endometrial carcinoma (EC). miR-486-5p dysregulation is observed in several tumor types, but the roles of miR-486-5p in EC are hardly ever studied.

Objective: This study aimed to analyze the expression profile of miR-486-5p in tumor tissues and serum samples of patients with EC and explore the target prediction, function analysis and validation in immortal cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S246841DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266516PMC

Efficacy of panniculectomy-combined surgery in superobese patients with endometrial cancer: A case report and literature review.

Int J Surg Case Rep 2020 Jun 6;72:99-103. Epub 2020 Jun 6.

Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago, Tottori, 683-5804, Japan.

Introduction: Panniculectomy is regarded as an effective approach in highly obese patients with endometrial cancer to improve surgical access or space of the surgical field.

Presentation Of Case: A 66-year-old nulliparous woman was brought in from another hospital to our institute for newly diagnosed endometrial carcinoma. The patient was 158 cm in height and weighed 135. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2020.05.066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298323PMC

Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes.

Gynecol Oncol 2020 Jun 9. Epub 2020 Jun 9.

Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, United States of America.

Objective: To determine associations between adoption of Medicaid expansion (ME) and changes in insurance status, early stage diagnosis, and cancer survival among women with endometrial carcinoma (EC).

Methods: The National Cancer Database (NCDB) was queried for patients diagnosed with EC between the age 40-64 from 2004 to 2015. Difference-in-differences analysis quantified the impact of ME on the proportion of new EC diagnoses with insurance (vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.05.018DOI Listing

miR-544a Stimulates endometrial carcinoma growth via targeted inhibition of reversion-inducing cysteine-rich protein with Kazal motifs.

Mol Cell Probes 2020 Jun 7:101572. Epub 2020 Jun 7.

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, PR China. Electronic address:

Endometrial carcinoma (EC) is a female-specific malignant tumor. Although current treatments can achieve good outcomes and improve patient survival, there remains a high incidence of treatment-induced infertility, a serious side effect that is unacceptable to those of childbearing age. Studies have demonstrated that micro ribonucleic acids (microRNAs or miRNAs) such as miR-544a regulate tumor-related gene expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mcp.2020.101572DOI Listing

Prognostic impact of ABO Blood group on Type I endometrial cancer in a population of iranian patients.

Hum Antibodies 2020 May 29. Epub 2020 May 29.

Shahid Beheshti Hospital, Qom University of Medical sciences, School of Medicine, Qom, Iran.

Background: Inherited ABO blood group has been shown to play an important role in the pathogenesis of various gynecological cancers including endometrial carcinoma (EC).

Objective: Our study aimed to determine the prevalence of ABO blood groups in Iranian patients with EC and to investigate the relationship between the blood group and several clinicopathologic parameters in Imam Hossein Hospital.

Methods: One hundred and seventy-five EC patients were selected and analyzed for their clinicopathologic details including ABO blood group, age, menopausal status, body mass index (BMI), tumor grade, and stage of the International Federation of Obstetrics and Gynecology (FIGO). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/HAB-200416DOI Listing

LncRNA AFAP1-AS1 contributes to the progression of endometrial carcinoma by regulating miR-545-3p/VEGFA pathway.

Mol Cell Probes 2020 Jun 3:101606. Epub 2020 Jun 3.

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province, 710004, China. Electronic address:

Endometrial carcinoma (EC) accounts for 20%-30% of female reproductive tumors. Targeted therapy for EC has shown great advantages with small side effects. To improve the survival of EC patients, more new therapeutic targets need to be found. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mcp.2020.101606DOI Listing

Estrogen-ERα signaling and DNA hypomethylation co-regulate expression of stem cell protein PIWIL1 in ERα-positive endometrial cancer cells.

Cell Commun Signal 2020 Jun 5;18(1):84. Epub 2020 Jun 5.

Department of Obstetrics and Gynecology, Shanghai First Maternity and Infant Hospital, Tong Ji University School of Medicine, No. 536, Changle Road, Shanghai, 200080, China.

Background: We previously identified PIWIL1 as an oncogene involved in endometrial carcinogenesis. However, the mechanism of Piwil1 mediated regulation of tumorigenesis remains poorly understood.

Methods: The expression levels of target genes in endometrial cancer cells were detected by quantitative reverse transcription-PCR (RT-qPCR) and western blotting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12964-020-00563-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275358PMC

Prognosis Trend of Grade 2 Endometrioid Endometrial Carcinoma: Toward Grade 1 or 3?

Pathol Oncol Res 2020 Jun 2. Epub 2020 Jun 2.

Department of Obstetrics and Gynecology Faculty of Medicine, Çukurova University, 01330, Adana, Turkey.

Although the prognostic significance of grade in endometrial cancer is well known, grade 2 cases have not been evaluated separately in most of the previous studies. In this study, we aim to investigate whether the oncologic outcomes of grade 2 endometrioid endometrial carcinomas trend towards grade 1 or 3 tumors. Patients' records and pathological reports were reviewed retrospectively and eligible patients with endometrioid endometrial carcinoma were determined and distributed into 3 groups according to their 1988 International Federation of Gynecology and Obstetrics (FIGO) grade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-020-00836-wDOI Listing

Transvaginal ultrasound in evaluation and follow-up of ovarian granulosa cell tumors.

Int J Gynecol Cancer 2020 May 30. Epub 2020 May 30.

Department of Obstetrics and Gynecology, IRCCS Ospedale San Raffaele, Milano, Italy.

Objective: Ultrasound features of granulosa cell tumors of the ovary are still poorly defined. The aim of this study is to widen current knowledge on the role of sonographic gray scale and pattern recognition in the characterization of these tumors and to compare the ultrasound characteristics of primary diagnosis and recurrences.

Methods: Transvaginal ultrasound images of primary diagnosis or recurrences of histologically-confirmed granulosa cell tumors of the ovary were retrospectively retrieved from a dedicated database designed for the collection of clinical and ultrasound data from January 2001 to January 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001276DOI Listing

Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.

Pathol Oncol Res 2020 May 28. Epub 2020 May 28.

Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan.

The aim of this study was to investigate the association between the clinicopathologic factors and either expression or co-expression of mesothelin and cancer antigen (CA) 125 in endometrial serous carcinoma and mixed carcinomas including serous carcinoma. Between 1990 and 2017, patients with endometrial serous carcinoma and mixed carcinoma including serous carcinoma treated by total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either expression or co-expression of mesothelin and CA125 was evaluated by immunochemical analysis and the clinico-pathological features were retrospectively examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-020-00823-1DOI Listing

Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer?

Gynecol Oncol 2020 May 25. Epub 2020 May 25.

Anatomopathology Unit, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Objective: To investigate the diagnostic accuracy of endometrial biopsy performed with hysteroscopic direct visualization using the "grasp technique" for the detection of endometrial carcinoma (EC) histology type and tumor grade.

Methods: A cross-sectional study including the clinical and pathology records of patients with confirmed EC who underwent definitive surgery at University of Naples was performed. The preoperative diagnosis of endometrial tumor type and grade obtained using the hysteroscopy grasp technique was correlated with the final pathology specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.05.012DOI Listing

Prognostic Role of Krüppel-Like Factors 5, 9, and 11 in Endometrial Endometrioid Cancer.

Pathol Oncol Res 2020 May 25. Epub 2020 May 25.

Institute of Pathology, DAME, Academic Hospital of Udine, University of Udine, Udine, 33100, Italy.

Background And Objective: Krüppel-like factors (KLFs) are transcription factors with the ability to mediate cross-talk with signaling pathways involved in cell proliferation control, apoptosis, migration, and differentiation. They also appear to influence steroid hormone signaling through transcriptional networks involving steroid hormone receptors and members of the nuclear receptor family of transcription factors. Our study aims to evaluate the potential prognostic role of KLF5, KLF9, and KLF11 in endometrial cancer, and their correlation with hormonal receptor status and cellular proliferation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-020-00817-zDOI Listing

Comparison of perioperative outcomes and technical features using da Vinci Si and Xi robotic platforms for early stages of endometrial cancer.

J Robot Surg 2020 May 23. Epub 2020 May 23.

Division of Obstetrics and Gynecology, Department of Experimental and Clinical Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.

We directly compared perioperative outcomes and technical features between previous da Vinci Si and the newer Xi robotic platform during total hysterectomy plus salpingo-oophorectomy with or without lymphadenectomy for early-stage endometrial cancer. We retrospectively analyzed147 patients with histological confirmation of endometrial carcinoma stage IA: grade 1-2, 3 and stage IB: grade 1-2 who underwent surgery with da Vinci Si or Xi system between January 2016 and December 2018. Perioperative data, technical features and postoperative complications were considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11701-020-01091-6DOI Listing

Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.

PLoS Med 2020 May 15;17(5):e1003111. Epub 2020 May 15.

Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.

Background: Bayesian networks (BNs) are machine-learning-based computational models that visualize causal relationships and provide insight into the processes underlying disease progression, closely resembling clinical decision-making. Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer, and although several biomarkers are related to LNM, none of them are incorporated in clinical practice. The aim of this study was to develop and externally validate a preoperative BN to predict LNM and outcome in endometrial cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pmed.1003111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228042PMC

Integrative analysis of genomic and epigenetic regulation of endometrial cancer.

Aging (Albany NY) 2020 May 15;12(10):9260-9274. Epub 2020 May 15.

Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.

Endometrial carcinomas (EC) are characterized by high DNA copy numbers and DNA methylation aberrations. In this study, we sought to comprehensively explore the effect of these two factors on development and progression of EC by analyzing integrated genomic and epigenetic analysis to. We found high DNA copy number and DNA methylation abnormalities in EC, with 6308 copy-number variation genes (CNV-G) and 4376 methylation genes (MET-G). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.103202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288931PMC

Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.

Med Mol Morphol 2020 May 14. Epub 2020 May 14.

Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.

Mismatch repair protein deficiency (dMMR) is a favorable prognostic factor in colorectal cancer. It is also associated with aberrant expression of HLA class I molecules, which are required for cytotoxic T lymphocyte-mediated cancer immunotherapy. Because dMMR is frequently also found in endometrial cancers (ECs), we retrospectively investigated the expression of mismatch repair proteins and HLA class I molecules in 127 EC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00795-020-00254-6DOI Listing

A 14-Methylation-Driven Differentially Expressed RNA as a Signature for Overall Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.

DNA Cell Biol 2020 Jun 12;39(6):975-991. Epub 2020 May 12.

Center of Reproductive Medicine, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

DNA methylation has been implicated as an important mechanism for the development of uterine corpus endometrial carcinoma (UCEC), indicating that methylation-driven genes may be potential biomarkers for survival prediction. In this study, we aimed to identify a new prognostic methylation signature for UCEC based on differentially expressed genes (DEGs) and long noncoding RNAs (lncRNAs) (DELs). Sample-matched RNA-sequencing and methylation-array data were downloaded from The Cancer Genome Atlas database, by analysis of which a total of 269 DEGs and 4 DELs were identified to be methylation driven. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/dna.2019.5313DOI Listing
June 2020
2.055 Impact Factor

Expression of poly-ADP-ribose polymerase (PARP) in endometrial adenocarcinoma: Prognostic potential.

Pathol Res Pract 2020 Jun 21;216(6):152965. Epub 2020 Apr 21.

Cabell Huntington Hospital Laboratory, Department of Pathology, Marshall University Joan C. Edwards School of Medicine, Huntington, WV, 25701, USA.

Background: In the United States endometrial carcinoma is the most common female gynecologic malignancy. An average of more than 60,000 new cases of endometrial carcinomas have been diagnosed yearly over the past 5 years, with a higher incidence occurring in the central Appalachian states of Ohio and West Virginia. In the U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2020.152965DOI Listing
June 2020
1.562 Impact Factor

Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma.

J Oncol 2020 10;2020:1295613. Epub 2020 Apr 10.

Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University, Istanbul, Turkey.

Purpose: We aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma.

Methods: We evaluated 135 patients with clinically early-stage (Stage I-II) type II endometrial carcinoma and carcinosarcoma who underwent systematic pelvic and paraaortic lymph node dissection or who did not undergo any lymph node dissection.

Results: Overall survival (OS) and recurrence-free survivals (RFS) were significantly longer in the systematic lymph node dissection group (hazard ratio 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/1295613DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171670PMC

Does cervicovaginal cytology have a role in the diagnosis and surveillance of endometrial adenocarcinoma?

Diagn Cytopathol 2020 Jul 25;48(7):629-634. Epub 2020 Apr 25.

Department of Pathology, Izmir Katip Celebi University Ataturk Teaching and Research Hospital, Izmir, Turkey.

Objective: To examine the role of cervicovaginal cytology in diagnoses and surveillance of the patients with endometrial carcinoma (EC).

Methods: Patients who underwent EC surgery that included a follow-up were reviewed retrospectively. The cohort was limited to the patients who had an available cervical cytology result within 12 months before the primary surgery took place. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24444DOI Listing

Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.

Gynecol Oncol 2020 Jul 21;158(1):3-11. Epub 2020 Apr 21.

Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, Vancouver, BC, Canada. Electronic address:

Objective: Our aim was to characterize the pathological, molecular and clinical outcomes of clear cell carcinoma of the endometrium (CCC).

Methods: CCC underwent ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classification identifying four molecular subtypes: i) 'POLEmut' for ECs with pathogenic POLE mutations, ii) 'MMRd', if there is loss of mismatch repair proteins by immunohistochemistry (IHC), iii) 'p53wt' or iv) 'p53abn' based on p53 IHC staining. Clinicopathologic parameters, immune markers (CD3, CD8, CD79a, CD138, PD-1), ER, L1CAM, and outcomes were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.04.043DOI Listing

Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study.

Jpn J Clin Oncol 2020 Apr 23. Epub 2020 Apr 23.

Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.

Objective: This study compared the survival outcomes and the incidence of chemotherapy-related adverse events in endometrial cancer patients who received four and six cycles of adjuvant chemotherapy to examine the optimal number of adjuvant chemotherapy cycles.

Methods: A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy. Between-group differences of overall survival, disease-free survival, hematological and non-hematological toxicities were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyaa047DOI Listing

circTNFRSF21, a newly identified circular RNA promotes endometrial carcinoma pathogenesis through regulating miR-1227-MAPK13/ATF2 axis.

Aging (Albany NY) 2020 Apr 16;12(8):6774-6792. Epub 2020 Apr 16.

Department of Obstetrics and Gynecology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.

Background: Circular RNA is a type of non-coding RNA with great potential in regulating gene expression and associated with disease progression. However, the role of circular RNA in endometrial carcinoma (EC) remains largely unknown.

Results: In this study, we found that circTNFRSF21 was highly expressed in EC cells and tumor tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.103037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202486PMC

LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration.

J Ovarian Res 2020 Apr 15;13(1):37. Epub 2020 Apr 15.

Department of Obstetrics and Gynecology, Key Laboratory for Gynecologic Oncology Gansu Province, the First Hospital of Lanzhou University, Lanzhou City, Gansu Province, 730000, PR China.

Background: Although lncRNA CTBP1-AS2 has been functionally analyzed only in cardiomyocyte hypertrophy and diabetes, analysis of TCGA dataset revealed its downregulation in endometrial carcinoma (EC), indicating its involvement in EC.

Results: In this study we found that CTBP1-AS2 was downregulated in EC and correlated with poor survival. MiR-216a might form base pairs with CTBP1-AS2 based on RNA-RNA interaction, which was confirmed by luciferase activity assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-020-00639-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157983PMC

Downregulation of LncRNA-MEG3 promotes HTR8/SVneo cells apoptosis and attenuates its migration by repressing Notch1 signal in preeclampsia.

Authors:
Rongli Wang Li Zou

Reproduction 2020 Jul;160(1):21-29

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

A successful pregnancy crucially depends on well-regulated extravillous trophoblast migration and invasion. Maternally expressed gene 3 (MEG3) is a long noncoding RNA that plays an important role in regulating trophoblast cells cell function. As previously reported, the expression of MEG3 was reduced in preeclampsia, and downregulation of MEG3 could suppress trophoblast cells migration and promote its apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/REP-19-0614DOI Listing

LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy.

Int J Gynecol Pathol 2020 May;39(3):203-212

University of Virginia School of Medicine (L.A.F.) University of Virginia Department of Obstetrics and Gynecology, Division of Gynecologic Oncology (K.L.R.) University of Virginia Department of Pathology (A.M.M.), Charlottesville, Virginia.

LAG-3 is an immunosuppressive checkpoint molecule expressed on T cells. One of its ligands, GAL-3, can promote the progression of malignancy and has been identified on tumor cells. Both LAG-3 and GAL-3 are the targets of emerging immunotherapies, but have not been well-studied in endometrial carcinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000608DOI Listing

The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study.

Sci Rep 2020 Apr 6;10(1):5984. Epub 2020 Apr 6.

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, 100730, China.

Little is known about the epidemiological and clinicopathological characteristics of endometrial endometrioid carcinoma (EEC) coexisting with or arising in adenomyosis (EEC-A or EEC-AIA) due to their rarity. This study compared EEC-A and EEC-AIA with endometrial carcinoma without adenomyosis. Cases of endometrial cancer treated at the study center from June 1, 2010, to June 1, 2017, were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-63065-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136226PMC
April 2020
5.078 Impact Factor

Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.

Gynecol Oncol 2020 Jun 1;157(3):619-623. Epub 2020 Apr 1.

Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America.

Objective: We report the incidence of occult nodal metastasis in patients who underwent primary surgical staging for apparent early endometrioid or serous endometrial cancer with bilateral SLN mapping and enhanced pathology. Occult ovarian metastasis rates were also reported.

Methods: Patients with clinical stage I serous or endometrioid endometrial cancer who underwent primary staging surgery with successful bilateral SLN mapping from 1/2005-12/2018 were retrospectively evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.03.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293586PMC

Hsa_circ_0061140 promotes endometrial carcinoma progression via regulating miR-149-5p/STAT3.

Gene 2020 Jun 26;745:144625. Epub 2020 Mar 26.

Department of Obstetrics and Gynecology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.

Circular RNAs (circRNAs) are reported to participate in many diseases including tumorigenesis, which can modulate gene expression post-transcriptionally. Up to now, the detailed function of circRNAs in endometrial carcinoma (EC) progression are to be well established. hsa_circ_0061140 has been revealed to act as crucial regulators in several cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2020.144625DOI Listing

Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer.

Gynecol Oncol 2020 Jun 23;157(3):716-722. Epub 2020 Mar 23.

Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, United States of America. Electronic address:

Background: Among women diagnosed with non-endometrioid endometrial carcinoma (EC), we investigated associations between race/ethnicity and receipt of guideline-concordant treatment (GCT), as well as relationships between GCT and survival.

Methods: We used the National Cancer Database and identified 21,177 non-Hispanic White (NHW), 6657 non-Hispanic Black (NHB), 1689 Hispanic, and 903 Asian/Pacific Islander (AS/PI) women diagnosed with non-endometrioid EC between 2004 and 2014. Year-specific National Comprehensive Cancer Network (NCCN) guidelines were used to classify GCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.03.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293554PMC

UPF1 Participates in the Progression of Endometrial Cancer by Inhibiting the Expression of lncRNA PVT1.

Onco Targets Ther 2020 9;13:2103-2114. Epub 2020 Mar 9.

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang, People's Republic of China.

Background: Endometrial carcinoma (EC) is the primary cause of death associated with cancer globally. Thus, the possible molecular mechanism of EC needs further exploration. Up-frameshift protein 1 () is an ATPase depending on RNA/DNA and RNA helicase depending on ATP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S233149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074825PMC

Altered glycosylation of glycodelin in endometrial carcinoma.

Lab Invest 2020 Jul 23;100(7):1014-1025. Epub 2020 Mar 23.

Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Glycodelin is a major glycoprotein expressed in reproductive tissues, like secretory and decidualized endometrium. It has several reproduction related functions that are dependent on specific glycosylation, but it has also been found to drive differentiation of endometrial carcinoma cells toward a less malignant phenotype. Here we aimed to elucidate whether the glycosylation and function of glycodelin is altered in endometrial carcinoma as compared with a normal endometrium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41374-020-0411-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312397PMC

The LncRNA AL161431.1 targets miR-1252-5p and facilitates cellular proliferation and migration via MAPK signaling in endometrial carcinoma.

Authors:
Z-R Gu W Liu

Eur Rev Med Pharmacol Sci 2020 03;24(5):2294-2302

Department of Obstetrics and Gynecology, the 5th People's Hospital of Ji'nan, Ji'nan, Shandong Province, P.R. China.

Objective: The aim of this study was to determine the expression profile and the underlying mechanism of the long intergenic non-protein coding RNA AL161431.1 in EC (endometrial carcinoma).

Materials And Methods: In this study, the expression data for the lncRNA AL161431. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202003_20495DOI Listing

Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.

Cancer 2020 Jun 18;126(12):2775-2783. Epub 2020 Mar 18.

Department of Pathology, Penn State College of Medicine, Penn State Health, Hershey, Pennsylvania.

Background: Endometrial hyperplasia is a precursor to endometrioid adenocarcinoma (EMC), the most common uterine cancer. The likelihood of progression to carcinoma may be evaluated by histologic subclassification of endometrial hyperplasia, although these subclasses are subjective and only modestly reproducible among pathologists. Patient care would be improved by a more objective test to predict the risk of cancer progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32822DOI Listing

An integrated molecular profile of endometrioid ovarian cancer.

Gynecol Oncol 2020 Apr 3;157(1):55-61. Epub 2020 Mar 3.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address:

Objective: Endometrioid ovarian carcinoma (EOVC) is an uncommon subtype of epithelial ovarian carcinoma and its molecular characteristics have been incompletely described. Prior sequencing investigations have been limited to targeted gene panels. We performed whole-exome sequencing to build an unbiased genetic profile of molecular alterations in endometrioid ovarian tumors with a goal to better understand this disease in the context of epithelial ovarian cancer and endometrioid uterine cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.02.011DOI Listing

Correction: AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma.

Oncotarget 2020 Feb 18;11(7):755-757. Epub 2020 Feb 18.

Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.

[This corrects the article DOI: 10.18632/oncotarget.4708. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041935PMC
February 2020

LncRNA DCST1-AS1 Was Upregulated in Endometrial Carcinoma and May Sponge miR-92a-3p to Upregulate Notch1.

Cancer Manag Res 2020 18;12:1221-1227. Epub 2020 Feb 18.

Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, People's Republic of China.

Introduction: The functions of DCST1-AS1 have been investigated in liver cancer, while its role in endometrial carcinoma (EC) remains hardly known. This study aimed to analyze the role of DCST1-AS1 in EC.

Methods: Paired EC and non-tumor tissue samples were obtained from 62 EC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S234891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035894PMC
February 2020

Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.

DNA Cell Biol 2020 Apr 27;39(4):615-630. Epub 2020 Feb 27.

Department of Gynecology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

Uterine corpus endometrial carcinoma (UCEC) is one of the leading causes of death from gynecological cancer due to the high recurrence rate. A recent study indicated that molecular biomarkers can enhance the recurrence prediction power if they were integrated with clinical information. In this study, we attempted to identify a new multi-RNA-type-based molecular biomarker for predicting the recurrence risk and recurrence-free survival (RFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/dna.2019.5148DOI Listing

[Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].

Zhonghua Fu Chan Ke Za Zhi 2020 Jan;55(1):21-28

Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.

To analyze the clinical efficacy and pregnancy outcomes of fertility- preserving re-treatment in patients with recurrent atypical endometrial hyperplasia (AEH) and early stage endometrial carcinoma (EEC) after achieved complete remission (CR) of primary fertility-preserving therapy. There were 104 cases of AEH and EEC collected from 9 hospitals in the multi-center research network platform of fertility-preserving therapy of endometrial carcinoma in China from January 2005 to May 2019. Thirth-one cases of them relapsed from four hospitals mentioned above,who achieved CR after primary fertility-preserving therapy,was analyzed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-567X.2020.01.005DOI Listing
January 2020

Microcystic, Elongated and Fragmented Pattern Invasion Can Adversely Influence Preoperative Staging for Low-grade Endometrial Carcinoma.

Magn Reson Med Sci 2020 Feb 19. Epub 2020 Feb 19.

Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine.

Purpose: To investigate the influence of microcystic, elongated and fragmented (MELF) pattern invasion on preoperative evaluation of lymph node (LN) metastasis and myometrial invasion in patients with low-grade endometrial carcinoma.

Methods: The study included 192 consecutive patients with low-grade endometrial carcinoma who underwent preoperative computed tomography (CT) and magnetic resonance imaging (MRI), followed by surgery. One hundred sixty one of 192 patients underwent LN dissection and were analyzed for LN metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2463/mrms.mp.2019-0153DOI Listing
February 2020

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.

BMC Cancer 2020 Feb 17;20(1):127. Epub 2020 Feb 17.

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8575, Japan.

Background: Tumor microenvironment (TME) including the immune checkpoint system impacts prognosis in some types of malignancy. The aim of our study was to investigate the precise prognostic significance of the TME profile in endometrial carcinoma.

Methods: We performed immunohistochemistry of the TME proteins, PD-L1, PD-1, CD4, CD8, CD68, and VEGF in endometrial carcinomas from 221 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-6545-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027009PMC
February 2020

Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.

Mod Pathol 2020 Jul 14;33(7):1443-1452. Epub 2020 Feb 14.

Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

The pathogenesis of DNA mismatch repair (MMR)-deficient endometrial carcinoma (EC) is driven by inactivating methylation or less frequently mutation of an MMR gene (MLH1, PMS2, MSH2, or MSH6). This study evaluated the prognostic and clinicopathologic differences between methylation-linked and nonmethylated MMR-deficient endometrioid ECs. We performed MMR immunohistochemistry and methylation-specific multiplex ligation-dependent probe amplification, and classified 682 unselected endometrioid ECs as MMR proficient (MMRp, n = 438) and MMR deficient (MMRd, n = 244), with the latter subcategorized as methylated (MMRd Met) and nonmethylated tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0501-8DOI Listing

Proteogenomic Characterization of Endometrial Carcinoma.

Cell 2020 Feb 13;180(4):729-748.e26. Epub 2020 Feb 13.

Institute for Systems Genetics, NYU School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016, USA. Electronic address:

We undertook a comprehensive proteogenomic characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis revealed possible new consequences of perturbations to the p53 and Wnt/β-catenin pathways, identified a potential role for circRNAs in the epithelial-mesenchymal transition, and provided new information about proteomic markers of clinical and genomic tumor subgroups, including relationships to known druggable pathways. An extensive genome-wide acetylation survey yielded insights into regulatory mechanisms linking Wnt signaling and histone acetylation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2020.01.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233456PMC
February 2020
32.242 Impact Factor

Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models.

Cancers (Basel) 2020 Feb 6;12(2). Epub 2020 Feb 6.

Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.

Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by the lack of appropriate imaging modalities. Here, we describe molecular imaging of a near-infrared fluorescently labeled monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) as an in vivo imaging modality for visualization of orthotopic endometrial carcinoma PDX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12020370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072497PMC
February 2020

Endometrial carcinoma arising in one horn of a didelphys uterus.

Taiwan J Obstet Gynecol 2020 Jan;59(1):162-164

Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Kweishan, Taoyuan, Taiwan; Chang Gung University College of Medicine, Kweishan, Taoyuan, Taiwan. Electronic address:

Objective: Endometrial cancer in uterine anomalies is very rare. Currently, few cases with endometrial cancer coexistent with didelphys uterus are described. We present a case of a patient with carcinoma in one only horn of a didelphys uterus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjog.2019.11.028DOI Listing
January 2020